Earnings Alerts

Outstanding Sonic Healthcare (SHL) Earnings: 1H Revenue Surpasses Estimates

By February 20, 2024 No Comments
  • Sonic Healthcare‘s revenue for the first half of the year exceeded expectations, reaching A$4.31 billion compared to the estimated A$4.23 billion.
  • The company reported a net income of A$202.3 million.
  • An interim dividend per share is set at A$0.43.
  • Earnings before interest, taxes, depreciation, and amortization (Ebitda) came in at A$736.7 million, slightly above the estimate of A$736.1 million.
  • There have been 6 buys, 7 holds, and 4 sells of Sonic Healthcare stocks recently.

A look at Sonic Healthcare Smart Scores

FactorScoreMagnitude
Value3
Dividend2
Growth3
Resilience2
Momentum3
OVERALL SMART SCORE2.6

Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma

Sonic Healthcare, a leading medical diagnostics company, has a positive long-term outlook according to the Smartkarma Smart Scores. With a score of 3 for value and growth, the company is well-positioned for future success. Sonic Healthcare offers a range of pathology and diagnostic imaging services to medical professionals and patients in Australia, New Zealand, and Europe. Additionally, the company provides administrative services and facilities to medical practitioners. This diverse range of services, coupled with its strong scores in value and growth, make Sonic Healthcare a promising investment for the long-term.

Investors looking for stable returns may also find Sonic Healthcare appealing, as the company received a score of 2 for both dividend and resilience. This indicates that the company has a solid track record of paying dividends and is well-equipped to withstand any potential challenges in the future. With a momentum score of 3, Sonic Healthcare is also showing positive signs of growth and progress. Overall, based on the Smartkarma Smart Scores, Sonic Healthcare is a strong and reliable player in the medical diagnostics industry, making it a promising long-term investment option.


Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.


 

πŸ’‘ Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • βœ“ Unlimited Research Summaries
  • βœ“ Personalised Alerts
  • βœ“ Custom Watchlists
  • βœ“ Company Analytics and News
  • βœ“ Events & Webinars